Last updated: May 26, 2026
Clindamycin Phosphate in 5% Dextrose in Plastic Container suppliers: who manufactures IV clindamycin phosphate premix?
Executive summary: Suppliers for clindamycin phosphate in 5% dextrose, intravenous (IV), in a plastic container are the drugs’ label holders and IV compounding manufacturers that either (1) supply an FDA-approved ready-to-use premix product on the market or (2) produce the same premix configuration under contract manufacturing and/or repack/relabeled supply chains. Without specific product strength, container type (eg, ViaFlex/polyolefin), and FDA application identifier for the exact NDC, a complete, authoritative supplier list for this exact presentation cannot be produced.
Who supplies clindamycin phosphate in 5% dextrose in plastic containers?
A definitive supplier list depends on the exact marketed presentation, which is typically identified by the NDC and label configuration. “Clindamycin phosphate in 5% dextrose” is most commonly supplied as an IV infusion in premixed containers (often plastic), and supply can include:
What supply channels exist for this IV premix
- Original manufacturer / labeler: Holds the FDA application and markets the finished premix.
- Contract manufacturers: Manufacture drug product and/or package fill-finish under commercial supply agreements.
- Repackagers / relabelers: Buy bulk/finished product and relabel for downstream wholesalers/providers in some supply arrangements.
- Hospital/IDN purchasing intermediaries: May list “suppliers” as distributors, but the underlying drug product maker can differ.
Which product identifiers drive supplier mapping
- NDC (National Drug Code) for the finished premix
- Container material and system (plastic infusion system type)
- Volume and concentration (eg, mg/mL)
- Sterility and route (IV infusion)
- Labeler name on the package and corresponding SPL record
What NDC-labeled suppliers make clindamycin phosphate in 5% dextrose premix?
Answer (featured snippet style): The supplier is the NDC labeler for the specific clindamycin phosphate in 5% dextrose plastic container presentation on the market. Vendor lists in procurement systems should be matched back to the SPL/NDC labeler to identify the true manufacturer.
How to confirm a supplier from procurement data
- Match the procurement SKU to the NDC
- Use the NDC labeler name as the “supplier” for regulatory sourcing
- Track changes by NDC due to relabeling or supply substitutions
Which companies are the contract manufacturers for IV clindamycin dextrose premix?
Contract manufacturing for IV premix products usually sits behind public-facing labeler branding. A company can appear as a supplier in distribution records without being the drug product manufacturer. A credible supplier map must be anchored to:
- FDA application and manufacturing site (from regulatory submissions and label content)
- Packaging system type referenced on the label (plastic container family)
Without the exact NDC/manufacturing label system, it is not possible to produce a complete contract-manufacturer roster for this specific premix configuration.
Is there more than one plastic container system for clindamycin phosphate in 5% dextrose?
Yes. “Plastic container” can refer to multiple infusion packaging families (common examples in US IV lines include different polyolefin or elastomeric infusion systems). Container system differences can impact:
- supply availability
- container labeling
- compatibility testing requirements
- sourcing and lead times
For supplier identification, the packaging system must match the label.
How do wholesale distributors list suppliers for this product if manufacturers differ?
Wholesalers often list:
- “supplier” as the distributor delivering product, not the labeler/MAH
- “manufacturer” as the labeler printed on the label, not the actual fill-finish site
- “brand” as the marketed label, not the raw product
For accurate sourcing, procurement and compliance teams should reconcile vendor lists to:
- the NDC labeler
- the FDA label and SPL record
- the package insert for container/administration details
What formulation and strength variations affect supplier eligibility?
Supplier eligibility and substitution risk depend on the exact formulation:
- clindamycin phosphate form (not clindamycin base)
- dextrose concentration (5%)
- container and infusion configuration
- concentration and total volume
If a procurement spec does not lock NDC and presentation, supplier lists can become unreliable.
Key Takeaways
- The reliable way to identify suppliers for clindamycin phosphate in 5% dextrose in plastic container is to anchor to the specific NDC-labeled presentation and use the labeler/MAH as the regulatory supplier.
- Procurement “supplier” names may reflect distributors, relabelers, or contractors, so supplier mapping must be NDC-based.
- A complete, authoritative supplier roster for this exact presentation cannot be produced without the exact labeled product identifier.
FAQs
-
How do I identify the correct supplier for clindamycin phosphate in 5% dextrose without substitutions?
Use the exact NDC and match it to the SPL labeler.
-
Can different manufacturers supply the same clindamycin phosphate dextrose IV premix?
Yes, across time and NDC changes, but each NDC presentation can have a different labeler and manufacturing chain.
-
Do plastic container systems change substitution risk for this IV drug?
Yes, container system differences can change labeling, handling, and compatibility profiles.
-
Is the distributor the same as the pharmaceutical manufacturer for clindamycin phosphate IV premix?
Often no. Distributors can differ from the labeler/manufacturer.
-
What specs should be locked in procurement to secure the intended premix?
Lock NDC, strength, volume, dextrose concentration, and container system family referenced on-label.
References
- FDA National Drug Code Directory (NDC), Product and Labeler lookup. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-ndc-directory
- FDA SPL (Structured Product Labeling) via NDC and labeler records. https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-datasets
- FDA Orange Book (for applicable drug/device exclusivity mapping where relevant). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
